OCUDEX LIQ 0.1% .1 %
DEXAMETHASONE SODIUM PHOSPHATE : .1 % · DIN 01995022 · HERDT ET CHARTON INC.
Health Canada status: CANCELLED POST MARKET
What is OCUDEX LIQ 0.1%?
OCUDEX LIQ 0.1% .1 % contains DEXAMETHASONE SODIUM PHOSPHATE : .1 %. It is listed in the Health Canada Drug Product Database under DIN 01995022, held by HERDT ET CHARTON INC., supplied as LIQUID for OPHTHALMIC ; TOPICAL administration. Health Canada currently lists it as cancelled post market, status dated 17-Sep-1999. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
Product details and regulatory record
| DIN | 01995022 |
|---|---|
| Brand name | OCUDEX LIQ 0.1% |
| Generic / active ingredient | DEXAMETHASONE SODIUM PHOSPHATE : .1 % |
| Manufacturer | HERDT ET CHARTON INC. |
| Strength | .1 % |
| Dosage form | LIQUID |
| Route of administration | OPHTHALMIC ; TOPICAL |
| Schedule | Prescription |
| ATC code | S01BA01 DEXAMETHASONE |
| AHFS class | 52:08.00 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 17-Sep-1999 |
| Original market date | 1994-12-31 00:00:00 |
Is DEXAMETHASONE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Active — reported by STERIMAX INC (Tier 3 shortage DEXAMETHASONE SODIUM PHOSPHATE INJECTION, USP" aria-label="Actual Tier 3 shortage DEXAMETHASONE SODIUM P), last seen 04 Sep 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code S01BA01 DEXAMETHASONE. 3 of 4 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| MAXIDEX | 0.1 % | SUSPENSION | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 00042560 |
| MAXIDEX | 0.1 % | OINTMENT | NOVARTIS PHARMACEUTICALS CANADA INC | MARKETED | DIN 00042579 |
| OZURDEX | 0.7 MG | IMPLANT | ABBVIE CORPORATION | MARKETED | DIN 02363445 |
Who else supplies DEXAMETHASONE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. DEXAMETHASONE appears in 2222 registered pack listings across 13 markets, published on 11 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.